Idorsia’s aprocitentan improved key prognostic indicators in difficult-to-control hypertension

Switzerland’s Idorsia (SIX: IDIA) has announced the publication of a new analysis from the landmark Phase III PRECISION study.

The analysis, published in the Journal of Hypertension, examined the changes in variables derived from ambulatory blood pressure (BP) monitoring that are shown to drive better outcomes for patients at high risk of cardiovascular events.

Aprocitentan, which is sold under the brand names Tryvio and Jeraygo and is the first approved antihypertensive targeting the endothelin pathway, substantially lowered 24-hour BP in patients with confirmed resistant hypertension, with particularly pronounced effects at night.